Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

被引：0
|
作者：
Yuan Zong
Jiajia Yuan
Zhi Peng
Ming Lu
Xicheng Wang
Lin Shen
Jun Zhou
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷
关键词：
Advanced pancreatic ductal adenocarcinoma; Chemotherapy; Nab-paclitaxel; S-1; Gemcitabine; Objective response rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1529 / 1536
页数：7
相关论文
共 50 条
  • [31] Efficacy and safety of nab-paclitaxel plus s-1 in the first-line treatment of advanced pancreatic cancer.
    Zhang, Wen
    Du, Chun-Xia
    Sun, Yongkun
    Yang, Lin
    Cui, Chengxu
    Jiang, Zhichao
    Wang, Jinwan
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
    Yamamoto, Tomohisa
    Fujii, Tsutomu
    Hirano, Satoshi
    Motoi, Fuyuhiko
    Honda, Goro
    Uemura, Kenichiro
    Kitayama, Joji
    Unno, Michiaki
    Kodera, Yasuhiro
    Yamaue, Hiroki
    Shimokawa, Toshio
    Hashimoto, Daisuke
    Yamaki, So
    Yoshitomi, Hideyuki
    Miura, Fumihiko
    Ueno, Hideki
    Sekimoto, Mitsugu
    Satoi, Sohei
    TRIALS, 2022, 23 (01)
  • [33] Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
    Tomohisa Yamamoto
    Tsutomu Fujii
    Satoshi Hirano
    Fuyuhiko Motoi
    Goro Honda
    Kenichiro Uemura
    Joji Kitayama
    Michiaki Unno
    Yasuhiro Kodera
    Hiroki Yamaue
    Toshio Shimokawa
    Daisuke Hashimoto
    So Yamaki
    Hideyuki Yoshitomi
    Fumihiko Miura
    Hideki Ueno
    Mitsugu Sekimoto
    Sohei Satoi
    Trials, 23
  • [34] Clinical observation of nab-paclitaxel plus S-1 as first-line chemotherapy for advanced gastric cancer.
    Hu, Yi
    Sun, Danyang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
    Dean, A.
    Das, A.
    McNulty, M.
    Travers, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Gemcitabine plus nab-paclitaxel in Japan
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Ookawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [38] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [40] A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma
    Ielpo, Benedetto
    Caruso, Riccardo
    Duran, Hipolito
    Diaz, Eduardo
    Fabra, Isabel
    Malave, Luis
    Ferri, Valentina
    Alvarez, Rafael
    Cubillo, Antonio
    Plaza, Carlos
    Lazzaro, Sara
    Kalivaci, Denis
    Quijano, Yolanda
    Vicente, Emilio
    SURGICAL ONCOLOGY-OXFORD, 2017, 26 (04): : 402 - 410
12345